Generic Name and Formulations:
Trimethobenzamide HCl 300mg; caps.
Indications for TIGAN:
Treatment of post-op or gastroenteritis-associated nausea and vomiting.
Use lowest effective dose. 300mg 3–4 times daily. Elderly or renal impairment (CrCl <70mL/min/1.73m2): reduce dose by increasing the dosing interval.
Acute dystonic reactions. Extrapyramidal symptoms. May mask other serious disorders (eg, encephalopathy, metabolic imbalance). Children (Reye's syndrome). Monitor for hepatic impairment; discontinue if occurs. Renal impairment. Elderly. Pregnancy. Nursing mothers.
Potentiated by alcohol (avoid), other CNS depressants (eg, sedatives, hypnotics, opiates, anxiolytics, antipsychotics, anticholinergics); monitor.
Parkinson-like symptoms, drowsiness, blood dyscrasias, blurred vision, coma, seizures, depression, diarrhea, disorientation, dizziness, jaundice, hypotension (inj), headache, muscle cramps, opisthotonos; hepatotoxicity, hypersensitivity reactions.
Caps—100; Single-use vials (2mL)—25; Multi-dose vial (20mL)—1
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness